Email This Article

Headlines & Perspectives
Vytorin Risks Debated in Medical Journal
By Elizabeth Trotta
09/02/08 - 02:29 PM EDT
The cholesterol drug, produced by Schering-Plough and Merck, produced a higher rate of cancer vs. a control group in a recent study, but a larger analysis said the results are statistically insignificant.
Recipient's Email Address(es)
(Separate multiple addresses with a comma)
Your Email Address
Send a copy to myself
Your Message (optional)

Privacy Policy

The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.

Dow Jones S&P 500 NASDAQ 10-Year Note
10,291.26 1,098.51 2,166.90 34.74
Oil *
77.90
UP
44.29
UP
5.50
UP
15.82
DOWN
0.08
10 Yr
3.47%
SPDR Gold
109.60
+0.43%
+0.50%
+0.74%
-0.23%
Data delayed 20 minutes

Brokerage Partners